Publikationen

Funding for HIV/AIDS treatment is not keeping up with need, and appears to be shrinking. Funding shortfalls punish the early success of the last decade of ART scale-up, and threaten to have a devastating impact on people living with HIV/AIDS as well as efforts to prevent new infections.

Ärzte ohne Grenzen untersucht in einem Report den Beitrag der Bundesrepublik Deutschland an der Forschung zur Bekämpfung der genannten Krankheiten. Dem Bericht "Forschungszwerg Deutschland - kaum Forschungmittel für vernachlässigte Krankheiten" zufolge gab die deutsche Bundesregierung im Jahr 2007 nur 20,7 Mio. Euro für die Forschung an diesen Krankheiten aus.

WHO advocates treating more patients by starting antiretroviral therapy at an earlier stage and using higher-quality drugs. These measures will result in an increase in the number of infected people eligible for treatment. While beneficial, the new recommendations pose many challenges and come amid an unfavourable global environment.

Menschen in ärmeren Ländern sind besonders stark von Krankheiten betroffen. Viele Todesfälle ließen sich durch Prävention oder medizinische Behandlung verhindern, doch der Zugang zu Präventionsmaßnahmen und unentbehrlichen Arzneimitteln ist oft nicht gewährleistet. An den in ärmeren Ländern vorherrschenden Krankheiten wird viel zu wenig geforscht. Diese Publikation präsentiert neue Modelle der Forschungsförderung mit ihren Vor- und Nachteilen und berichtet über wichtige politische Beschlüsse zum Thema "Forschung für die Armen".

(hg. von Ärzte ohne Grenzen, eed, Buko-Pharma, Universities Allied for Essential Medicines Germany)

The current R&D system is driven by market forces, not health needs, and relies overwhelmingly on the patent system to recoup R&D costs by charging high prices for the medical tools that reach the market. The two key problems that this system creates is addressed in this briefing paper.

This report outlines some of the strategies, tools and policies that have supported the scaling up of treatment during the past decade as well as those that can address persistent or new challenges. The results are presented from a 23-country survey of how consistently these strategies are being implemented.

This document shows how health programmes can be designed to deliver antiretroviral drugs at a communits level.

The 15th edition of this publication gives an overview on drug prices and their quality, introduces the main actors in the field and the threats and challenges in keeping the prices of ARVs down.

This document serves as an update to “Out of the Dark”, a report published by MSF in October 2011, highlighting the need to prioritise the long-neglected area of paediatric tuberculosis (TB). This update will outline the key improvements and setbacks—the ‘highlights’ and ‘lowlights’—that have occurred over the last year.

This document serves as an update to “Out of the Dark”, a report published by MSF in October 2011, highlighting the need to prioritise the long-neglected area of paediatric tuberculosis (TB). This update will outline the key improvements and setbacks—the ‘highlights’ and ‘lowlights’—that have occurred over the last year.